The role of molecular imaging in drug discovery and development

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 2, 2008, Pages 349-353

  Hargreaves, R J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; IBRITUMOMAB TIUXETAN; TOSITUMOMAB I 131; TRACER;

ALZHEIMER DISEASE; ATHEROSCLEROSIS; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DESIGN; DRUG INDICATION; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR IMAGING; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SENSITIVITY ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ULTRASOUND;

ANIMALS; ANTINEOPLASTIC AGENTS; ATHEROSCLEROSIS; BIOMARKERS, PHARMACOLOGICAL; CARDIOVASCULAR AGENTS; CENTRAL NERVOUS SYSTEM AGENTS; DIAGNOSTIC IMAGING; DRUG DESIGN; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; NEOPLASMS; OPTICS; PATIENT SELECTION; POSITRON-EMISSION TOMOGRAPHY; TECHNOLOGY, PHARMACEUTICAL; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; ULTRASONOGRAPHY;

EID: 38349095953     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100467     Document Type: Review

References (25)

1. Cohen, C.M. A path to improved pharmaceutical productivity. Nat. Rev. Drug Discov. 2, 751-753 (2003).
2. Frank, R. & Hargreaves, R. Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discov. 2, 566-580 (2003).
3. Rudin, M. & Weissleder, R. Molecular imaging in drug discovery and development. Nat. Rev. Drug Discov. 2, 123-131 (2003).
4. Massoud, T.F. & Gambhir, S.S. Integrating non-invasive molecular imaging into molecular medicine - an evolving paradigm. Trends Mol. Med. 13, 183-191 (2007).
5. Sosnovik, D.E. & Weissleder, R. Emerging concepts in molecular MRI. Curr. Opin. Biotechnol. 18, 4-10 (2007).
6. Gross, S. & Piwnica-Worms, D. Spying on cancer - molecular imaging in vivo with genetically encoded reporters. Cancer Cell 7, 5-15 (2005).
7. Schuster, D.P. The opportunities and challenges of developing imaging biomarkers to study lung function and disease. Am. J. Respir. Crit. Care Med. 176, 224-230 (2007).
8. Medarova, Z., Pham, W., Farrar, C., Petkova, V. & Moore, A. In vivo imaging of siRNA delivery and silencing in tumors. Nat. Med. 13, 372-377 (2007).
9. Bednar, B., Zhang, G.-J., Williams, D.L. Jr., Hargreaves, R. & Sur, C. Optical molecular imaging in drug discovery and clinical development. Expert Opin. Drug Discov. 2, 65-85 (2007).
10. MI Gateway. Society of Nuclear Medicine molecular imaging center of Excellence. 〈http://www.snm.org/mi〉
11. Pomper, M.G. & Lee, J.S. Small animal imaging in drug development. Current Pharmaceutical Design 11, 3247-3272 (2005).
12. Deroose, C.M. et al. Multimodality imaging of tumor xenografts and metastases in mice with combined small-animal PET, small-animal CT and bioluminesence imaging. J. Nuc. Med. 48, 295-303 (2007).
13. Rueger, M.A. et al. Role of in vivo imaging of the central nervous system for developing novel drugs. Q. J. Nucl. Med. Mol. Imaging 51, 164-181 (2007).
14. Hammoud, D.A., Hoffman J.M. & Pomper, M. Molecular neuroimaging: from conventional to emerging techniques. Radiology 245, 21-42 (2007).
15. Burns, H.D. et al. [18F]MK-9470, a positron emission tomography (PET)tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc. Natl. Acad. Sci. USA 104, 9800-9805 (2007).
16. Borsook, D., Becerra, L. & Hargreaves, R.J. A role for fMRI in CNS drug development. Nature Rev. Drug Discov. 5, 411-424 (2006).
17. Erondu, N. et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab. 4, 275-282 (2006).
18. Bergström, M. et al. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol. Psychiatry 55, 1007-1012 (2004).
19. Keller, M. et al. Lack of efficacy of the substance P (neurokinin 1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol. Psychiatry 59, 216-223 (2006).
20. MacManus, M.P. et al. Overview of early response assessment in lymphoma with FDG-PET. Cancer Imaging 7, 10-18 (2007).
21. fNIH lung and lymphoma [18F] FDG consortia. 〈http://www. biomarkersconsortium.org/index.php?option=com_content&task=view&id= 93&Itemid=143〉 (2007).
22. Hargreaves, R. & Wagner, J. Imaging as a biomarker for decision making in drug development. In In Vivo MR Techniques in Drug Discovery and Development (ed. Beckmann, N.) Ch. 3, 31-46 (Taylor & Francis, New York, 2006).
23. Jaffer, F.A., Libby, P. & Weissleder, R. Molecular Imaging of cardiovascular disease. Circulation 116, 1052-1061 (2007).
24. Alzheimer's Disease Neuroimaging Initiative (ADNI). 〈http://www.nia. nih.gov/Alzheimers/ResearchInformation/ClinicalTrials/ADNI.htm〉 (2007).
25. Hanahan, D. & Weinberg, R.A. Hallmarks of cancer. Cell 100, 57-70 (2000).